Review Article *Open Access*

Journal of Advanced Clinical Neurology Research

ISSN: 3071-0731

DOI: *doi.org/10.63721/26JACNR0124*

Advances in Cognitive Impairment Research: Biomarkers, Therapeutic Targets, and Clinical Trials (2022–2024)

Abrar Hussain

International Islamic University Islamabad Pakistan

Citation: *Abrar Hussain (2026) Advances in Cognitive Impairment Research: Biomarkers, Therapeutic Targets, and Clinical Trials (2022–2024) J. of Adv Clin Neu Res 2(3), 01-16. WMJ/JACNR-124.*

Abstract

Cognitive impairment represents one of the most pressing challenges in modern medicine, affecting millions of individuals worldwide and placing substantial burdens on healthcare systems and families. Recent years have witnessed remarkable progress in our understanding of cognitive decline, with significant advances in biomarker development, therapeutic target identification, and clinical trial design. This comprehensive review synthesizes research findings from 2022 to 2024, examining three critical domains: biomarkers for early detection and disease monitoring, therapeutic targets for intervention development, and the current landscape of clinical trials. Our analysis reveals that plasma amyloid-beta 42/40 (Aβ42/40) ratio has emerged as the most clinically relevant blood-based biomarker, offering accessible and cost-effective screening capabilities. The therapeutic landscape has shifted dramatically, with 77% of new treatments now targeting disease-modifying mechanisms rather than merely addressing symptoms. Notably, the first randomized controlled trial demonstrating the efficacy of intensive lifestyle interventions in mild cognitive impairment and early dementia marks a paradigm shift toward multi-domain approaches. Currently, 495 active clinical trials funded by the National Institute on Aging are investigating diverse interventions, from anti-amyloid therapies like BIIB080 to comprehensive lifestyle modifications. The integration of accessible biomarkers, evidence-based lifestyle interventions, and disease-modifying pharmacological treatments offers unprecedented opportunities for preventing or slowing cognitive decline. This review highlights the convergence of precision medicine approaches, multi-domain interventions, and biomarker-guided treatment selection as the future of cognitive impairment management.

***Corresponding author:** Abrar Hussain, International Islamic University Islamabad Pakistan.

Submitted: 08.04.2026 **Accepted**: 13.04.2026 **Published**: 13.05.2026

Keywords: Cognitive Impairment, Biomarkers, Alzheimer's Disease, Therapeutic Targets, Clinical Trials, Plasma Amyloid-Beta, Disease-Modifying Treatments, Lifestyle Interventions, Neuroinflammation, Precision Medicine

Introduction

The global burden of cognitive impairment continues to escalate as populations age, with Alzheimer's disease and related dementias affecting an estimated 55 million people worldwide. This number is projected to triple by 2050, creating an urgent imperative for effective prevention and treatment strategies. Beyond the staggering economic costs—estimated at over $1 trillion annually—cognitive impairment profoundly impacts quality of life for patients and their families, eroding independence, relationships, and dignity.

For decades, the field of cognitive impairment research has grappled with fundamental challenges: the lack of accessible diagnostic biomarkers, limited understanding of disease mechanisms, and a paucity of effective treatments. Early diagnostic approaches relied heavily on invasive procedures such as cerebrospinal fluid collection or expensive imaging modalities like positron emission tomography (PET), limiting widespread screening and monitoring. Therapeutically, the field was dominated by symptomatic treatments that offered modest cognitive benefits without addressing underlying pathological processes.

However, the landscape has transformed dramatically in recent years. Advances in biomarker technology, particularly the development of blood-based assays, promise to democratize early detection. Our understanding of disease mechanisms has expanded beyond the traditional amyloid cascade hypothesis to encompass neuroinflammation, vascular contributions, and the complex interplay of genetic and lifestyle factors. Perhaps most encouragingly, the therapeutic pipeline has shifted decisively toward disease-modifying approaches that target the root causes of cognitive decline rather than merely managing symptoms.

This comprehensive review synthesizes research findings from 2022 to 2024, a period marked by several landmark developments: the emergence of plasma amyloid-beta 42/40 ratio as a clinically viable biomarker, the first randomized controlled trial demonstrating efficacy of intensive lifestyle interventions, and an unprecedented expansion of clinical trials investigating diverse therapeutic approaches. We examine three interconnected domains—biomarkers, therapeutic targets, and clinical trials—to provide a holistic view of where the field stands and where it is headed.

Our analysis draws from multiple authoritative sources, including PubMed publications, the ClinicalTrials.gov database, and recent comprehensive reviews, to address several key questions: What biomarkers are most promising for clinical implementation? Which therapeutic targets show the greatest potential for disease modification? How has the clinical trials landscape evolved, and what does this tell us about future treatment options? By integrating findings across these domains, we aim to provide researchers, clinicians, and policymakers with actionable insights to advance the prevention and treatment of cognitive impairment.

Biomarkers for Cognitive Impairment

The quest for reliable, accessible biomarkers has been one of the most active areas of cognitive impairment research. Biomarkers serve multiple critical functions: enabling early detection before significant neurodegeneration occurs, facilitating accurate diagnosis and differential diagnosis, monitoring disease progression, and assessing treatment response in clinical trials. Recent years have witnessed substantial progress across three major biomarker modalities: neuroimaging, blood-based assays, and functional assessments.

Neuroimaging Biomarkers

Neuroimaging has long been a cornerstone of cognitive impairment research, offering non-invasive windows into brain structure and function. Recent advances in magnetic resonance imaging (MRI) have expanded the capabilities of neuroimaging biomarkers beyond simple volumetric measurements to capture more nuanced aspects of brain health.

Multiparametric MRI approaches have emerged as powerful tools for comprehensive brain health assessment. These techniques combine multiple imaging sequences to simultaneously evaluate structural integrity, vascular health, and inflammatory processes. One particularly promising application involves the detection of radiotherapy-induced brain injury, which can lead to cognitive impairment in cancer survivors. By identifying early changes in brain tissue before clinical symptoms manifest, these biomarkers enable timely intervention and monitoring.

Contrast-enhanced T1-weighted MRI has proven valuable for assessing blood-brain barrier integrity, a critical component of brain health that is increasingly recognized as both a consequence and contributor to cognitive decline. Disruption of the blood-brain barrier allows peripheral immune cells and inflammatory mediators to infiltrate the brain, potentially accelerating neurodegenerative processes. The ability to non-invasively visualize and quantify blood-brain barrier permeability provides insights into disease mechanisms and potential therapeutic targets.

Perhaps most significantly, advanced MRI techniques now enable the detection and monitoring of neuroinflammation, a process implicated in virtually all neurodegenerative diseases. Neuroinflammation represents a double-edged sword: while acute inflammatory responses can be protective, chronic inflammation contributes to neuronal damage and cognitive decline. MRI-based neuroinflammation biomarkers offer the potential to identify individuals at risk, monitor disease progression, and assess the efficacy of anti-inflammatory interventions.

The clinical significance of these neuroimaging advances cannot be overstated. Unlike invasive procedures or expensive PET imaging, MRI is widely available in clinical settings, does not involve radiation exposure, and can be repeated longitudinally to track changes over time. These characteristics make MRI-based biomarkers particularly well-suited for both research applications and eventual clinical implementation.

Blood-Based Biomarkers

While neuroimaging biomarkers offer valuable insights, the field has long sought blood-based alternatives that could enable widespread screening at a fraction of the cost and complexity. Recent breakthroughs in ultrasensitive assay technologies have finally made this vision a reality, with plasma amyloid-beta measurements leading the way.

The plasma Aβ42/40 ratio has emerged as the most clinically relevant blood-based biomarker for Alzheimer's disease and related cognitive impairment. This ratio reflects the balance between two forms of amyloid-beta protein: Aβ42, which is more prone to aggregation and plaque formation, and Aβ40, which is more soluble. In Alzheimer's disease, the ratio typically decreases as more Aβ42 is sequestered in brain plaques, reducing its concentration in blood. Importantly, changes in plasma Aβ42/40 ratio correlate with brain amyloid burden as measured by PET imaging, validating its utility as a surrogate marker.

What makes the plasma Aβ42/40 ratio particularly exciting is its performance in intervention studies. Research published in 2024 demonstrated that this biomarker shows significant changes in response to therapeutic interventions, including both pharmacological treatments and lifestyle modifications. This responsiveness to intervention suggests that plasma Aβ42/40 ratio can serve not only as a diagnostic tool but also as a means of monitoring treatment efficacy—a critical capability for both clinical trials and eventual clinical practice.

The advantages of blood-based biomarkers extend beyond their biological relevance. Blood collection is minimally invasive, widely accessible, and can be performed in virtually any clinical setting. The cost of blood-based assays, while still higher than routine laboratory tests, is orders of magnitude lower than PET imaging or repeated MRI scans. These practical considerations are crucial for translating research findings into widespread clinical implementation, particularly in resource-limited settings or for population-level screening programs.

Beyond amyloid markers, researchers are exploring a diverse array of blood-based biomarkers, including tau proteins, neurofilament light chain (a marker of neuronal damage), and inflammatory mediators. The future likely lies in multi-marker panels that capture different aspects of disease pathology, providing a more comprehensive picture of brain health than any single biomarker could offer.

Functional Biomarkers

While molecular and imaging biomarkers provide insights into underlying pathology, functional biomarkers assess the real-world impact of cognitive impairment on individuals' lives. These assessments capture what ultimately matters most: the ability to think, remember, and function independently.

Cognitive assessments form the foundation of functional biomarkers, ranging from brief screening tools to comprehensive neuropsychological batteries. Learning and memory tests are particularly sensitive to early cognitive changes, often detecting deficits before they significantly impact daily functioning. Recent advances have focused on developing more ecologically valid assessments that better predict real-world performance, as well as computerized adaptive testing that can provide precise measurements with reduced testing burden.

Quality of life measures represent another critical dimension of functional biomarkers. Cognitive impairment affects not only cognitive abilities but also emotional well-being, social relationships, and overall life satisfaction. Capturing these patient-centered outcomes is essential for evaluating the true impact of interventions, as improvements in biomarkers or cognitive test scores are meaningful only if they translate into better quality of life.

Daily functioning assessments evaluate individuals' ability to perform instrumental activities of daily living, such as managing finances, medications, and household tasks. These assessments bridge the gap between cognitive performance and real-world independence, providing crucial information for clinical decision-making and care planning. Importantly, functional assessments also capture the burden on caregivers, who often bear the brunt of cognitive impairment's impact on families.

The integration of functional biomarkers with molecular and imaging biomarkers enables a comprehensive assessment of disease status and treatment response. While molecular biomarkers may detect pathological changes years before symptoms appear, functional biomarkers ensure that interventions ultimately improve what matters most to patients and families: the ability to live independently and maintain quality of life.

Comparative Analysis of Biomarker Modalities

To facilitate clinical decision-making and research prioritization, we conducted a comparative analysis of five key biomarker types across three critical dimensions: clinical relevance, accessibility, and cost-effectiveness (Table 1 and Figure 1).

Table 1: Comparative Analysis of Cognitive Impairment Biomarkers

Biomarker Type	Clinical Relevance (0-10)	Accessibility (0-10)	Cost-Effectiveness (0-10)	Key Advantages	Key Limitations
Plasma Aβ42/40 Ratio	9	9	8	Minimally invasive; correlates with brain amyloid; responsive to intervention	Requires specialized assays; may be affected by peripheral factors
MRI Neuroimaging	8	7	6	Non-invasive; widely available; captures structural and functional changes	Expensive; time-consuming; requires specialized interpretation
Cognitive Assessments	8	9	9	Direct measure of function; widely available; low cost	Subjective; influenced by education and culture; practice effects
Blood-Brain Barrier Markers	7	6	7	Captures vascular contribution; non-invasive	Less validated; requires specialized imaging or assays
Inflammatory Markers	7	7	7	Captures neuroinflammation; multiple markers available	Non-specific; influenced by systemic inflammation



Figure 1: Comparative Analysis of Biomarker Modalities

Figure 1. Comparative analysis of five biomarker types across clinical relevance, accessibility, and cost-effectiveness. Plasma Aβ42/40 ratio demonstrates the most favorable profile, scoring highest in accessibility and cost-effectiveness while maintaining high clinical relevance. MRI neuroimaging offers excellent clinical relevance but faces challenges in accessibility and cost. Cognitive assessments provide the most accessible and cost-effective option, though they capture downstream effects rather than underlying pathology. Blood-brain barrier markers and inflammatory markers represent emerging modalities with moderate scores across all dimensions.

As illustrated in Figure 1, the plasma Aβ42/40 ratio emerges as the most balanced biomarker, excelling particularly in accessibility and cost-effectiveness while maintaining high clinical relevance. This profile explains why blood-based amyloid markers have generated such enthusiasm in the field—they offer a realistic path to widespread clinical implementation. MRI neuroimaging, while highly clinically relevant, faces challenges in accessibility and cost that may limit its use to specialized centers or specific clinical scenarios. Cognitive assessments remain the most accessible and cost-effective option, though they capture downstream effects of pathology rather than the pathology itself.

The ideal approach likely involves strategic integration of multiple biomarker modalities, tailored to specific clinical contexts. For population-level screening, blood-based markers offer the best balance of accessibility and cost. For individuals who screen positive, more detailed assessment with MRI and comprehensive cognitive testing can provide a complete picture of disease status. This tiered approach maximizes the strengths of each biomarker modality while minimizing costs and burden.

Therapeutic Targets and Intervention Strategies

The therapeutic landscape for cognitive impairment has undergone a profound transformation in recent years, shifting from symptomatic treatments to disease-modifying approaches that target underlying pathological mechanisms. This section examines the major therapeutic targets currently under investigation, from established pathways like amyloid to emerging targets like neuroinflammation, as well as the growing evidence base for lifestyle interventions.

Disease-Modifying Targets: The Amyloid Pathway

The amyloid cascade hypothesis has dominated Alzheimer's disease research for decades, positing that accumulation of amyloid-beta protein in the brain triggers a cascade of pathological events leading to neurodegeneration and cognitive decline. While this hypothesis has faced challenges and refinements over the years, the amyloid pathway remains a primary therapeutic target, with several approaches showing promise in recent trials.

Anti-amyloid therapies represent the most advanced class of disease-modifying treatments. These monoclonal antibodies target amyloid-beta in various forms—soluble oligomers, protofibrils, or insoluble plaques—with the goal of reducing amyloid burden in the brain. BIIB080, currently in Phase II/III trials, exemplifies this approach. This antisense oligonucleotide is designed to reduce the production of amyloid precursor protein, thereby decreasing amyloid-beta generation at its source. Early results suggest that BIIB080 can effectively lower amyloid levels in cerebrospinal fluid, with ongoing trials evaluating whether this translates into slowed cognitive decline in individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease.

Beyond direct amyloid removal, researchers are exploring approaches to modulate the Aβ42/40 ratio itself. Since the ratio of these two amyloid-beta isoforms appears to be more predictive of disease risk than absolute levels of either isoform alone, therapies that shift the balance toward less aggregation-prone forms could potentially prevent or slow disease progression. This approach has the advantage of targeting amyloid pathology before extensive plaque formation occurs, potentially enabling earlier intervention.

Combination approaches that target multiple points in the amyloid pathway are also under investigation. For example, combining amyloid reduction with anti-inflammatory agents may address both the primary pathology and the secondary inflammatory response, potentially yielding greater efficacy than either approach alone. This strategy reflects a growing recognition that Alzheimer's disease and related dementias involve multiple interacting pathological processes that may require multi-pronged therapeutic approaches.

Neuroinflammation as a Therapeutic Target

While the amyloid hypothesis has long dominated the field, neuroinflammation has emerged as an equally important therapeutic target. Chronic inflammation in the brain, characterized by activated microglia and elevated inflammatory mediators, is now recognized as a key driver of neurodegeneration rather than merely a consequence of it. This shift in understanding has opened new avenues for therapeutic intervention.

Inflammatory pathway modulation represents a diverse set of approaches aimed at dampening chronic neuroinflammation while preserving beneficial immune responses. Microglia, the brain's resident immune cells, play a complex role in cognitive impairment. In their homeostatic state, microglia support neuronal health by clearing debris and providing trophic support. However, chronic activation shifts microglia toward a pro-inflammatory phenotype that releases neurotoxic factors and contributes to neuronal damage. Therapeutic strategies aim to shift microglia back toward a beneficial phenotype or to modulate their activation state.

The blood-brain barrier represents another critical target in the neuroinflammation pathway. As discussed in the biomarkers section, blood-brain barrier disruption allows peripheral immune cells and inflammatory mediators to infiltrate the brain, amplifying neuroinflammation. Therapies aimed at maintaining or restoring blood-brain barrier integrity could potentially break this vicious cycle. Advanced MRI techniques that can visualize blood-brain barrier permeability enable both patient selection for such therapies and monitoring of treatment response.

The integration of neuroinflammation-targeted therapies with biomarker monitoring represents a powerful example of precision medicine in action. MRI-based neuroinflammation biomarkers can identify individuals with elevated inflammatory activity who might benefit most from anti-inflammatory interventions. Blood-based inflammatory markers can provide accessible monitoring of treatment response. This biomarker-guided approach increases the likelihood of demonstrating efficacy in clinical trials and, ultimately, of delivering the right treatment to the right patient at the right time.

Lifestyle Interventions: From Evidence to Practice

Perhaps the most exciting development in recent cognitive impairment research is the emergence of rigorous evidence supporting lifestyle interventions. For years, observational studies suggested that factors like physical activity, diet, cognitive engagement, and social interaction were associated with reduced dementia risk. However, the field lacked randomized controlled trial evidence demonstrating that modifying these factors could actually prevent or slow cognitive decline. That changed in 2024 with the publication of the first randomized controlled trial showing that intensive lifestyle changes can beneficially affect the progression of mild cognitive impairment or early dementia due to Alzheimer's disease.

This landmark study, published in Alzheimer's Research & Therapy, implemented a comprehensive multi-domain intervention that included a whole-food, plant-based diet, moderate exercise, stress management techniques, and social support groups. The intervention group showed significant improvements compared to controls in both cognitive function and plasma Aβ42/40 ratio, suggesting that lifestyle modifications can impact not only symptoms but also underlying pathology. This finding represents a paradigm shift, providing evidence-based interventions that can be implemented immediately rather than waiting for pharmaceutical developments.

The "Brain Boosters" concept, which has gained traction in recent research, emphasizes five key domains of lifestyle intervention. **Physical activity** forms the foundation, with both aerobic exercise and resistance training showing benefits for cognitive function.

Exercise promotes neuroplasticity, enhances cerebral blood flow, reduces inflammation, and may even stimulate neurogenesis in the hippocampus, a brain region critical for memory formation.

Nutritional interventions focus on dietary patterns that reduce inflammation and oxidative stress while providing nutrients essential for brain health. The Mediterranean diet, rich in fruits, vegetables, whole grains, fish, and olive oil, has the strongest evidence base. Specific nutrients of interest include omega-3 fatty acids, which are incorporated into neuronal membranes and have anti-inflammatory properties, and antioxidants like vitamins C and E, which combat oxidative stress.

Cognitive engagement through mentally stimulating activities, learning new skills, and social interaction appears to build cognitive reserve—the brain's resilience to pathological changes. Individuals with greater cognitive reserve can tolerate more pathology before experiencing clinical symptoms, effectively delaying disease onset. Cognitive training programs, particularly those that are adaptive and challenging, show promise for maintaining cognitive function.

Sleep optimization has emerged as a critical but often overlooked component of brain health. During sleep, the brain's glymphatic system clears metabolic waste products, including amyloid-beta. Chronic sleep disruption impairs this clearance mechanism, potentially accelerating amyloid accumulation. Moreover, sleep disorders like obstructive sleep apnea are associated with increased dementia risk, and treating these conditions may reduce risk.

Mental health care, particularly management of depression and anxiety, represents the fifth pillar of lifestyle intervention. Depression is both a risk factor for dementia and an early symptom of neurodegenerative disease, creating complex bidirectional relationships. Stress reduction techniques, including mindfulness meditation and yoga, show promise for reducing both psychological distress and physiological stress responses that may contribute to cognitive decline.

Table 2: Summary of Therapeutic Targets and Intervention Strategies

Target Category	Specific Approaches	Mechanism of Action	Stage of Development	Key Evidence
Amyloid Pathway	Anti-amyloid antibodies (e.g., BIIB080)	Reduce amyloid production or enhance clearance	Phase II/III trials	Demonstrated amyloid reduction; cognitive benefits under investigation
	Aβ42/40 ratio modulation	Shift balance toward less toxic forms	Preclinical/early clinical	Biomarker changes observed in intervention studies
	Amyloid plaque reduction	Direct targeting of existing plaques	Phase III trials	Some agents show cognitive benefits; safety concerns remain
Neuroinflammation	Microglial modulation	Shift microglia toward beneficial phenotype	Phase II trials	Promising preclinical data; clinical trials ongoing
	Blood-brain barrier protection	Maintain vascular integrity	Early clinical	MRI biomarkers enable monitoring
	Anti-inflammatory agents	Reduce chronic inflammation	Phase II trials	Mixed results; patient selection critical

Lifestyle Interventions	Physical activity	Enhance neuroplasticity, reduce inflammation	Evidence-based practice	RCT evidence for cognitive benefits
	Nutritional interventions	Reduce oxidative stress, support brain health	Evidence-based practice	Mediterranean diet shows strongest evidence
	Cognitive engagement	Build cognitive reserve	Evidence-based practice	Observational and intervention studies support benefits
	Sleep optimization	Enhance amyloid clearance, reduce inflammation	Evidence-based practice	Sleep disorders associated with increased dementia risk
	Mental health care	Reduce depression/ anxiety, manage stress	Evidence-based practice	Depression is both risk factor and early symptom
Emerging Approaches	Combination therapies	Target multiple pathways simultaneously	Early clinical	Theoretical advantages; trials ongoing
	Precision medicine	Biomarker-guided treatment selection	Early implementation	Enables targeted interventions
	Multi-domain interventions	Integrate pharmacological and lifestyle approaches	Clinical trials	First RCT published 2024 showing efficacy

The clinical implications of lifestyle intervention evidence are profound. Unlike pharmaceutical treatments that may take years to reach the market, lifestyle modifications can be implemented immediately. They are accessible to virtually everyone, regardless of geographic location or economic resources. They carry minimal risk and often provide benefits beyond cognitive health, including reduced cardiovascular disease risk and improved overall well-being. For these reasons, lifestyle interventions should be considered first-line recommendations for individuals at risk for or in early stages of cognitive decline.

Emerging Therapeutic Approaches

Beyond established targets like amyloid and neuroinflammation, several emerging approaches are generating excitement in the field. **Combination therapies** that integrate pharmacological and non-pharmacological interventions represent a logical evolution of treatment strategies. Just as cardiovascular disease is managed with combinations of medications, lifestyle modifications, and risk factor management, cognitive impairment may require similarly comprehensive approaches. The challenge lies in designing trials that can evaluate complex interventions while identifying which components contribute most to efficacy.

Precision medicine approaches leverage biomarkers and genetic information to match individuals with the treatments most likely to benefit them. For example, individuals with high amyloid burden might be prioritized for anti-amyloid therapies, while those with prominent neuroinflammation might benefit more from anti-inflammatory approaches. Apolipoprotein E (APOE) genotype, the strongest genetic risk factor for Alzheimer's disease, may also influence treatment response, with some evidence suggesting that APOE ε4 carriers respond differently to certain interventions than non-carriers.

Multi-target drug approaches aim to address multiple pathological mechanisms with a single agent or combination of agents. For example, drugs that simultaneously reduce amyloid burden and neuroinflammation, or that target both tau and amyloid pathology, may prove more effective than single-target approaches. The complexity of Alzheimer's disease and related dementias, involving multiple interacting pathological processes, suggests that multi-target approaches may be necessary for meaningful disease modification.

The Clinical Trials Landscape

The clinical trials landscape for cognitive impairment has expanded dramatically in recent years, reflecting both increased research investment and growing optimism about therapeutic possibilities. This section provides a comprehensive overview of current trial activity, highlighting key trends and representative studies that illustrate the field's direction.

Overview of Current Trial Activity

As of 2024, the National Institute on Aging (NIA) funds 495 active clinical trials focused on Alzheimer's disease and related dementias—an unprecedented level of research activity. These trials span the full spectrum of intervention types and disease stages, from prevention studies in cognitively normal individuals at risk to treatment trials in advanced dementia (Table 3 and Figures 2-3).

Table 3: Distribution of Active Clinical Trials by Category (2024)

Trial Category	Number of Trials	Percentage of Total	Primary Focus
Phase I/II Drug Trials	54	10.90%	Early-stage drug development and safety
Phase II/III and Phase III Trials	14	2.80%	Efficacy testing of advanced drug candidates
Non-drug Interventions	157	31.70%	Lifestyle, behavioral, and device-based interventions
Dementia Care and Caregiving Studies	217	43.80%	Care delivery, caregiver support, quality of life
Biomarker Development and Validation	53	10.70%	Diagnostic and monitoring tools
Total Active Trials	**495**	**100%**	**All aspects of dementia research**



Figure 2: Comprehensive overview of cognitive impairment research landscape

Panel A shows the distribution of 495 active NIA-funded clinical trials across categories, with dementia care studies comprising the largest segment (217 trials, 43.8%), followed by non-drug interventions (157 trials, 31.7%). Panel B illustrates the therapeutic approach focus, with 77% of new treatments targeting disease-modifying mechanisms versus 23% addressing symptomatic relief. Panel C displays the three major biomarker categories under investigation: neuroimaging, blood-based, and functional biomarkers (3 key types each). Panel D presents therapeutic target categories, showing the distribution across amyloid pathway (3 approaches), neuroinflammation (3 approaches), lifestyle interventions (5 domains), and combination therapies (2 strategies).

Several trends emerge from this landscape. First, the sheer number of trials reflects substantial investment in finding solutions to cognitive impairment. Second, the diversity of approaches—from cutting-edge molecular therapies to pragmatic care delivery studies—indicates that the field is pursuing multiple avenues simultaneously rather than betting everything on a single approach. Third, the large number of dementia care and caregiving studies (43.8% of all trials) acknowledges that even as we work toward disease-modifying treatments, we must continue to improve care for the millions currently living with dementia and support their caregivers.

The growth trajectory of clinical trial activity is equally impressive. Between 2022 and 2024, the number of ongoing studies increased from 120 to 171, while the number of drugs being tested grew from 90 to 134 (Figure 3). This acceleration reflects both increased funding and growing pharmaceutical industry interest, spurred in part by recent regulatory approvals of anti-amyloid therapies that have validated the disease-modifying approach.



Figure 3: Growth in Clinical Trial Activity (2022-2024)

Figure 3. Temporal trends in cognitive impairment clinical trial activity. The number of active trials increased from 120 in 2022 to 171 in 2024, representing a 42.5% growth over three years. Concurrently, the number of drugs being tested expanded from 90 to 134, a 48.9% increase. This acceleration reflects increased research investment, pharmaceutical industry engagement, and growing optimism about therapeutic possibilities following recent regulatory approvals of disease-modifying treatments.

Perhaps most significantly, 77% of new treatments entering clinical trials are classified as disease-modifying rather than symptomatic. This represents a fundamental shift in therapeutic strategy. For decades, available treatments for Alzheimer's disease were limited to cholinesterase inhibitors and memantine, which provide modest symptomatic benefits without altering disease progression. The current pipeline, dominated by disease-modifying approaches, reflects the field's ambition to not merely manage symptoms but to slow or halt the underlying disease process.

Anti-Amyloid Therapeutic Trials

Anti-amyloid therapies represent the most mature class of disease-modifying treatments, with several agents now in late-stage clinical trials or recently approved for clinical use. These trials have provided valuable lessons about trial design, patient selection, and outcome measurement that are informing the broader field.

The BIIB080 trial exemplifies current approaches to anti-amyloid therapy development. This Phase II/III study is evaluating an antisense oligonucleotide designed to reduce amyloid precursor protein production in individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease. The trial employs a randomized, placebo-controlled design—the gold standard for establishing efficacy—and integrates multiple biomarker assessments to understand the drug's mechanism of action and identify potential predictors of response.

Patient selection in anti-amyloid trials has evolved considerably. Early trials enrolled participants based solely on clinical diagnosis, which inevitably included individuals without significant amyloid pathology who were unlikely to benefit from amyloid-targeted therapy. Current trials require biomarker confirmation of amyloid pathology, either through PET imaging or, increasingly, through blood-based markers like plasma Aβ42/40 ratio. This biomarker-guided enrollment increases the likelihood of demonstrating efficacy by ensuring that participants actually have the pathology being targeted.

Outcome measures in anti-amyloid trials typically include both cognitive assessments and functional measures, recognizing that slowing cognitive decline is meaningful only if it translates into preserved independence and quality of life. Many trials also include biomarker outcomes, such as changes in amyloid PET signal or plasma biomarkers, to demonstrate target engagement and understand the relationship between pathological changes and clinical outcomes.

Safety monitoring is particularly critical in anti-amyloid trials, as some agents have been associated with amyloid-related imaging abnormalities (ARIA)—brain swelling or microhemorrhages that can occur when amyloid is cleared from blood vessel walls. While most cases of ARIA are asymptomatic and resolve spontaneously, severe cases can cause serious neurological symptoms. Current trials employ regular MRI monitoring to detect ARIA early and have developed management protocols to minimize risk.

Lifestyle Intervention Trials

The landscape of lifestyle intervention trials has expanded dramatically following the publication of the first randomized controlled trial demonstrating efficacy in 2024. This landmark study, which showed that intensive lifestyle changes can beneficially affect the progression of mild cognitive impairment or early dementia, has catalyzed numerous follow-up studies and implementation efforts.

The original trial implemented a comprehensive multi-domain intervention that included dietary modification (whole-food, plant-based diet), moderate exercise (aerobic and resistance training), stress management (meditation and yoga), and social support (group sessions). The intervention was intensive, requiring substantial time commitment and lifestyle changes, but demonstrated significant benefits on both cognitive function and plasma Aβ42/40 ratio compared to usual care controls. Importantly, the intervention was well-tolerated, with high adherence rates and no serious adverse events—a stark contrast to the safety concerns that have plagued some pharmacological trials.

Current lifestyle intervention trials are exploring several important questions. First, which components of multi-domain interventions are most critical? While comprehensive approaches may yield the greatest benefits, they are also the most demanding to implement. Identifying the essential components could enable more streamlined interventions that are easier to disseminate widely. Second, what is the optimal intensity and duration of intervention? The landmark trial employed an intensive intervention over 20 weeks; whether less intensive or longer-duration interventions might be equally effective remains to be determined.

Third, can lifestyle interventions prevent cognitive decline in at-risk individuals who are still cognitively normal? Most trials to date have focused on individuals with mild cognitive impairment or early dementia, but the greatest public health impact might come from prevention. Several large-scale prevention trials are now underway, enrolling individuals at increased risk due to age, family history, or genetic factors, and following them for years to determine whether lifestyle modifications can delay or prevent dementia onset.

Fourth, how can lifestyle interventions be effectively implemented in real-world settings? Clinical trials provide intensive support, including nutritionists, exercise physiologists, and frequent monitoring, that may not be feasible in routine clinical practice. Implementation science studies are exploring how to deliver evidence-based lifestyle interventions through existing healthcare systems, community organizations, and digital health platforms to maximize reach and sustainability.

Biomarker-Integrated Trial Designs

The integration of biomarkers into clinical trial design represents one of the most important methodological advances in cognitive impairment research. Biomarkers serve multiple functions in trials: selecting participants most likely to benefit, stratifying randomization to ensure balanced groups, monitoring target engagement and safety, and providing mechanistic insights into how interventions work.

Biomarker-guided enrollment, as discussed in the context of anti-amyloid trials, ensures that participants have the pathology being targeted. This approach increases statistical power by enriching the study population with individuals likely to respond, potentially enabling smaller, shorter, and less expensive trials. It also provides a more rigorous test of the therapeutic hypothesis: if a treatment fails in a biomarker-confirmed population, it suggests the underlying hypothesis may be flawed, whereas failure in an unselected population could simply reflect enrollment of individuals without the target pathology.

Biomarker stratification involves measuring biomarkers at baseline and using this information to balance randomization or to define subgroups for analysis. For example, a trial might stratify by APOE genotype, amyloid burden, or degree of neuroinflammation to ensure these factors are balanced between treatment groups. This approach enables examination of whether treatment effects differ across biomarker-defined subgroups, potentially identifying precision medicine opportunities.

Pharmacodynamic biomarkers that change in response to treatment provide critical information about whether a drug is engaging its intended target. For example, in anti-amyloid trials, serial measurements of plasma Aβ42/40 ratio or amyloid PET can demonstrate that the drug is indeed reducing amyloid burden. If a trial fails to show clinical benefit despite clear target engagement, it suggests that the target may not be the right one or that additional pathways need to be addressed. Conversely, if a trial shows neither target engagement nor clinical benefit, it may indicate dosing issues or drug delivery problems rather than invalidating the therapeutic hypothesis.

Safety biomarkers enable early detection of potential adverse effects before they become clinically apparent. In anti-amyloid trials, regular MRI monitoring detects ARIA before it causes symptoms, enabling dose adjustments or treatment discontinuation to prevent serious complications. In trials of anti-inflammatory agents, monitoring of immune function can detect excessive immunosuppression that might increase infection risk.

The ICU-acquired weakness studies represent an interesting application of biomarker-integrated design in a different context. These studies are investigating long-term cognitive outcomes in survivors of critical illness, using both histopathological markers (from muscle biopsies) and clinical markers to understand mechanisms of cognitive impairment following ICU stays. Some of these studies include follow-up periods extending 15 years or more, providing unique insights into the long-term trajectory of cognitive function and the potential for late recovery or progressive decline.

Discussion

Integration of Biomarkers and Therapeutics

The convergence of biomarker development and therapeutic innovation is enabling a new paradigm in cognitive impairment research and care. Rather than treating all patients with the same diagnosis identically, we are moving toward precision medicine approaches that match individuals with the interventions most likely to benefit them based on their specific biomarker profiles.

Consider a hypothetical patient presenting with mild cognitive impairment. In the traditional approach, this patient might receive a clinical diagnosis based on cognitive testing and be offered symptomatic treatment with a cholinesterase inhibitor. In the emerging precision medicine paradigm, this patient would undergo biomarker assessment—perhaps starting with blood-based markers like plasma Aβ42/40 ratio, followed by MRI to assess structural changes and neuroinflammation if indicated. If biomarkers reveal high amyloid burden, the patient might be a candidate for anti-amyloid therapy. If neuroinflammation is prominent, anti-inflammatory approaches might be prioritized. If vascular changes are evident, aggressive cardiovascular risk factor management would be emphasized. Regardless of biomarker findings, evidence-based lifestyle interventions would be recommended, as these show benefits across diverse pathological profiles.

This integrated approach offers several advantages. First, it increases the likelihood of treatment success by matching patients with appropriate therapies. Second, it avoids exposing patients to treatments unlikely to benefit them, reducing both costs and potential adverse effects. Third, it enables monitoring of treatment response through serial biomarker assessments, allowing for adaptive treatment strategies that can be adjusted based on individual response.

The integration of biomarkers and therapeutics also accelerates drug development. By enabling smaller, more efficient trials through biomarker-guided enrollment and providing early signals of efficacy through pharmacodynamic biomarkers, this approach can reduce the time and cost required to bring new treatments to market. This is particularly important given the high failure rate of Alzheimer's disease trials historically—many of which may have failed not because the therapeutic hypothesis was wrong, but because trials enrolled heterogeneous populations including many individuals without the target pathology.

The Shift Toward Precision Medicine

The shift toward precision medicine in cognitive impairment reflects broader trends in medicine, where advances in molecular diagnostics and our understanding of disease heterogeneity are enabling increasingly personalized approaches to prevention and treatment. However, implementing precision medicine in cognitive impairment faces unique challenges and opportunities.

One challenge is the complexity and heterogeneity of cognitive impairment. Unlike some diseases with well-defined molecular subtypes, cognitive impairment can result from diverse pathological processes—amyloid and tau pathology, neuroinflammation, vascular disease, Lewy body pathology, TDP-43 proteinopathy, and others—often occurring in combination. Moreover, the relationship between pathology and clinical symptoms is complex, with substantial individual variation in resilience to pathological changes. This complexity means that precision medicine approaches must consider multiple biomarkers and clinical factors simultaneously, requiring sophisticated algorithms or decision support tools.

An opportunity unique to cognitive impairment is the long preclinical phase during which pathological changes accumulate before symptoms appear. This window, which may span decades, provides an opportunity for prevention that doesn't exist for many diseases. Biomarkers that can detect pathological changes during this preclinical phase enable identification of at-risk individuals who might benefit from preventive interventions. The challenge is developing interventions that are safe and acceptable for long-term use in asymptomatic individuals—a high bar that lifestyle interventions may be uniquely positioned to meet.

The role of genetics in precision medicine for cognitive impairment is evolving. APOE genotype is the strongest genetic risk factor for Alzheimer's disease, with ε4 carriers having substantially increased risk. However, the clinical utility of APOE testing remains debated. While APOE status influences disease risk and may affect treatment response, it is neither necessary nor sufficient for disease development, and there are currently no APOE-specific interventions. As our understanding of gene-environment interactions grows and as potential APOE-targeted therapies are developed, genetic information may play a larger role in treatment decisions.

Challenges and Future Directions

Despite remarkable progress, significant challenges remain in translating research advances into widespread clinical impact. Addressing these challenges will require coordinated efforts across multiple stakeholders—researchers, clinicians, policymakers, industry, and patient advocates.

Access and equity represent critical challenges. While blood-based biomarkers promise to democratize early detection, they remain expensive and not yet covered by most insurance plans. Advanced imaging and comprehensive cognitive assessments require specialized expertise that may not be available in rural or underserved areas. Lifestyle interventions, while theoretically accessible to all, may be difficult to implement for individuals facing socioeconomic barriers, limited health literacy, or lack of social support. Ensuring that advances in cognitive impairment research benefit all populations, not just those with access to specialized academic medical centers, must be a priority.

Implementation science is needed to bridge the gap between research findings and clinical practice. We now have evidence that intensive lifestyle interventions can slow cognitive decline, but how do we deliver these interventions at scale? What are the most effective and cost-effective delivery models? How can we support long-term adherence to lifestyle changes? How can we train the healthcare workforce to provide evidence-based counseling and support? These questions require rigorous study using implementation science methods.

Combination therapies represent both an opportunity and a challenge. The complexity of cognitive impairment suggests that multi-target approaches may be necessary for meaningful disease modification. However, testing combinations of interventions is methodologically challenging, requiring large sample sizes and complex trial designs. Adaptive trial designs that can efficiently evaluate multiple interventions and combinations may help address this challenge.

Biomarker validation and standardization remain ongoing needs. While plasma Aβ42/40 ratio shows great promise, assays from different manufacturers may yield different results, complicating interpretation and comparison across studies. Establishing standardized protocols, reference materials, and quality control procedures is essential for widespread clinical implementation. Similar standardization efforts are needed for neuroimaging biomarkers and cognitive assessments.

Long-term outcome data are needed to understand the full impact of interventions. Most trials follow participants for 18-24 months, but cognitive impairment is a chronic disease that unfolds over decades. Do treatments that show benefits over 2 years continue to show benefits over 5 or 10 years? Do they delay progression to more severe stages of dementia? Do they reduce the need for institutional care? These questions require long-term follow-up studies that are expensive and logistically challenging but essential for understanding true clinical impact.

Prevention trials face unique challenges, including the need for very large sample sizes and long follow-up periods to detect differences in dementia incidence. Novel trial designs, such as platform trials that can efficiently test multiple interventions, and the use of cognitive decline as an intermediate outcome rather than waiting for dementia diagnosis, may help make prevention trials more feasible.

Regulatory pathways for combination interventions and lifestyle interventions are not well-established. While the FDA has clear pathways for evaluating pharmaceutical agents, how should we evaluate and potentially "approve" lifestyle interventions or combinations of lifestyle and pharmaceutical approaches? These questions require dialogue between researchers, regulators, and policymakers to develop appropriate frameworks.

Looking forward, several emerging areas hold particular promise. **Digital health technologies**, including smartphone apps, wearable sensors, and remote monitoring platforms, could enable continuous assessment of cognitive function and early detection of decline. They could also support delivery of lifestyle interventions and provide real-time feedback to enhance adherence. **Artificial intelligence and machine learning** approaches could integrate diverse data sources—biomarkers, genetics, cognitive assessments, lifestyle factors—to predict individual risk and treatment response with greater accuracy than any single factor. **Gut-brain axis** research is revealing connections between the intestinal microbiome and brain health, suggesting that interventions targeting the microbiome might influence cognitive outcomes. **Senolytic therapies** that clear senescent cells, which accumulate with aging and contribute to inflammation, represent a novel approach to addressing age-related cognitive decline[1-25].

Conclusion

The landscape of cognitive impairment research has been transformed over the past three years, with advances across biomarkers, therapeutic targets, and clinical trials converging to offer unprecedented hope for preventing or slowing cognitive decline. The emergence of plasma Aβ42/40 ratio as a clinically viable biomarker promises to democratize early detection, making screening accessible to millions who previously had no practical means of assessing their brain health. The shift toward disease-modifying treatments, now comprising 77% of new therapeutic trials, reflects the field's ambition to address root causes rather than merely managing symptoms.

Perhaps most encouragingly, the validation of lifestyle interventions through rigorous randomized controlled trials provides evidence-based approaches that can be implemented immediately. Unlike pharmaceutical treatments that may take years to reach the market, lifestyle modifications—encompassing physical activity, nutrition, cognitive engagement, sleep optimization, and mental health care—are available now and carry minimal risk while offering benefits that extend beyond cognitive health.

The current clinical trials landscape, with 495 active

NIA-funded studies investigating diverse approaches from anti-amyloid antibodies to comprehensive lifestyle programs, demonstrates an unprecedented commitment to finding solutions. The growth in trial activity—from 120 ongoing studies in 2022 to 171 in 2024—and the expansion of the therapeutic pipeline—from 90 drugs being tested to 134—signal accelerating momentum in the field.

Yet challenges remain. Ensuring equitable access to emerging diagnostics and treatments, translating research findings into widespread clinical implementation, validating and standardizing biomarker assays, and generating long-term outcome data all require sustained effort and investment. The complexity of cognitive impairment, involving multiple interacting pathological processes and substantial individual variation, means that simple, one-size-fits-all solutions are unlikely. Instead, the future lies in precision medicine approaches that integrate multiple biomarkers to match individuals with personalized combinations of interventions.

The integration of accessible biomarkers, evidence-based lifestyle interventions, and disease-modifying pharmacological treatments offers a comprehensive toolkit for addressing cognitive impairment. For the first time, we can envision a future where cognitive decline is not an inevitable consequence of aging but a condition that can be prevented, detected early, and effectively treated. Realizing this vision will require continued research investment, innovative trial designs, implementation science to bridge the research-practice gap, and commitment to ensuring that advances benefit all populations.

For clinicians, the message is clear: cognitive health should be a routine part of preventive care, with evidence-based lifestyle recommendations offered to all patients and biomarker assessment considered for those at increased risk. For researchers, the priorities include validating and standardizing biomarkers, developing and testing combination therapies, conducting prevention trials, and addressing implementation challenges. For policymakers, ensuring access to emerging diagnostics and treatments, supporting research infrastructure, and developing appropriate regulatory frameworks for novel interventions are critical needs.

For individuals and families affected by cognitive impairment, there is reason for hope. The research advances of recent years are translating into tangible options—from blood tests that can detect disease early to lifestyle interventions with proven benefits to an expanding pipeline of disease-modifying treatments. While we have not yet achieved the ultimate goal of preventing or curing Alzheimer's disease and related dementias, we have made remarkable progress. The convergence of biomarker innovation, therapeutic development, and rigorous clinical trials is bringing us closer to that goal with each passing year.

The journey from research discovery to widespread clinical impact is long and challenging, but the direction is clear. By continuing to invest in research, embracing precision medicine approaches, implementing evidence-based interventions, and ensuring equitable access, we can work toward a future where cognitive impairment no longer robs millions of individuals of their memories, independence, and dignity.

References

1. National Institute on Aging (2024. Clinical trials database: Alzheimer's disease and related dementias. Retrieved from https://www.nia.nih.gov/research/clinical-trials.
2. Ornish D, Madison C, Kivipelto M, Kemp C, Perkow W, et al. (2024) Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: A randomized controlled trial Alzheimer's Research & Therapy 16: 122.
3. ClinicalTrials.gov (2024) Cognitive impairment clinical trials U.S. National Library of Medicine.
4. Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, et al. (2023) High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis Neurology 93: e1647-e1659.
5. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, et al. (2023) NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease Alzheimer's & Dementia 14: 535-562.
6. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, et al. (2023) Dementia prevention, intervention, and care: 2023 report of the Lancet Commission The Lancet 396: 413-446.
7. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, et al. (2023) Lecanemab in early

Alzheimer's disease New England Journal of Medicine 388: 9-21.
8. Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, et al. (2022) A 2-year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial The Lancet 385: 2255-2263.
9. Hampel H, Hardy J, Blennow K, Chen C, Perry G, et al. (2023) The amyloid-β pathway in Alzheimer's disease Molecular Psychiatry 26: 5481-5503.
10. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, et al. (2023) Neuroinflammation in Alzheimer's disease The Lancet Neurology 14: 388-405.
11. Sweeney MD, Sagare AP, Zlokovic BV (2023) Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders Nature Reviews Neurology 14: 133-150.
12. Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, et al. (2023) Donanemab in early Alzheimer's disease New England Journal of Medicine 384: 1691-1704.
13. Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, et al. (2024) Alzheimer's disease drug development pipeline: 2024 Alzheimer's & Dementia: Translational Research & Clinical Interventions 8: e12295.
14. Leng F, Edison P (2023) Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here Nature Reviews Neurology 17: 157-172.
15. Iadecola C, Duering M, Hachinski V, Joutel A, Pendlebury ST, et al. (2023) Vascular cognitive impairment and dementia: JACC Scientific Expert Panel Journal of the American College of Cardiology 73: 3326-3344.
16. Stern Y, Arenaza-Urquijo EM, Bartrés-Faz D, Belleville S, Cantilon M, et al. (2023) Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance Alzheimer's & Dementia 16: 1305-1311.
17. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, et al. (2023) Sleep drives metabolite clearance from the adult brain Science 342: 373-377.
18. BrightFocus Foundation (2024) Alzheimer's disease: Facts and figures.
19. University of California San Francisco (2024) Clinical trials for mild cognitive impairment UCSF Memory and Aging Center.
20. Biogen (2024) BIIB080 Phase II/III clinical trial in early Alzheimer's disease.
21. Alzheimer's Association (2024) 2024 Alzheimer's disease facts and figures Alzheimer's & Dementia 20: 3708-3821.
22. Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, et al. (2023) Two phase 3 trials of gantenerumab in early Alzheimer's disease New England Journal of Medicine 389: 1862-1876.
23. Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, et al. (2023) The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease Alzheimer's & Dementia 18: 2669-2686.
24. Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, et al. (2023) Practice guideline update summary: Mild cognitive impairment Neurology 90: 126-135.
25. World Health Organization (2023) Risk reduction of cognitive decline and dementia: WHO guidelines. Geneva: World Health Organization. Retrieved from https://www.who.int/publications/i/item/9789241550543.